84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]許京華,李東升,李記天.健脾補腎中藥對惡性骨腫瘤化療后骨髓抑制患者外周血象的影響[J].中醫(yī)正骨,2021,33(04):38-43.
　XU Jinghua,LI Dongsheng,LI Jitian.Effects of Jianpi Bushen(健脾補腎)traditional Chinese medicine on peripheral hemogram of patients with myelo-suppression after chemotherapy for treatment of malignant bone tumors[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(04):38-43.
點擊復制

健脾補腎中藥對惡性骨腫瘤化療后骨髓抑制患者外周血象的影響()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第33卷
期數(shù):
2021年04期
頁碼:
38-43
欄目:
臨床研究
出版日期:
2021-04-20

文章信息/Info

Title:
Effects of Jianpi Bushen(健脾補腎)traditional Chinese medicine on peripheral hemogram of patients with myelo-suppression after chemotherapy for treatment of malignant bone tumors
作者:
許京華; 李東升; 李記天
(河南省洛陽正骨醫(yī)院/河南省骨科醫(yī)院,河南 鄭州 450016)
Author(s):
XU Jinghua; LI Dongsheng; LI Jitian
Luoyang Orthopedic-Traumatological Hospital,Zhengzhou 450016,Henan,China
關鍵詞:
骨腫瘤;  抗腫瘤聯(lián)合化療方案;  骨髓抑制;  健脾;  補腎;  中藥療法;  骨肉瘤;  肉瘤; Ewing;  組織細胞瘤; 惡性纖維;  轉(zhuǎn)移癌
Keywords:
bone neoplasms;  antineoplastic combined chemotherapy protocols;  marrow suppression;  STRENGTHENING SPLEEN;  REINFORCING KIDNEY;  DRUG THERAPY(TCD);  osteosarcoma;  sarcoma; Ewing;  histiocytoma; malignant fibrous;  metastatic carcinoma
摘要:
目的:觀察健脾補腎中藥對惡性骨腫瘤化療后骨髓抑制患者外周血象的影響。方法:將符合要求的60例惡性骨腫瘤化療后骨髓抑制患者隨機分為2組,每組30例。聯(lián)合治療組采用健脾補腎中藥口服聯(lián)合重組人粒細胞集落刺激因子皮下注射治療,單純西藥組采用重組人粒細胞集落刺激因子皮下注射治療; 均連續(xù)治療7 d為1個療程,共治療1個療程。比較2組患者治療前后外周血液中白細胞計數(shù)、血紅蛋白含量及血小板計數(shù),并評估白細胞、血紅蛋白及血小板抑制程度。治療結(jié)束1周后,評價患者臨床癥狀改善情況及生活質(zhì)量。結(jié)果:①白細胞計數(shù)。治療前2組患者的白細胞計數(shù)比較,差異無統(tǒng)計學意義[(3.28±0.64)×109個·L-1,(3.19±0.76)×109個·L-1,t=0.566,P=0.576]; 治療結(jié)束1周后,2組患者的白細胞計數(shù)均高于治療前(t=-6.606,P=0.000; t=-3.583,P=0.000),且聯(lián)合治療組患者的白細胞計數(shù)高于單純西藥組[(8.68±1.75)×109個·L-1,(4.63±1.20)×109個·L-1,t=10.954,P=0.000]。②血紅蛋白含量。治療前2組患者的血紅蛋白含量比較,差異無統(tǒng)計學意義[(112.47±10.05)g·L-1,(108.63±9.67)g·L-1,t=-1.941,P=0.062]; 治療結(jié)束1周后,2組患者的血紅蛋白含量均高于治療前(t=-11.750,P=0.000; t=-5.695,P=0.000),且聯(lián)合治療組患者的血紅蛋白含量高于單純西藥組[(140.83±17.36)g·L-1,(126.87±15.56)g·L-1,t=4.331,P=0.000]。③血小板計數(shù)。治療前2組患者的血小板計數(shù)比較,差異無統(tǒng)計學意義[(121.10±23.51)×109個·L-1,(126.90±30.52)×109個·L-1,t=-1.250,P=0.221]; 治療結(jié)束1周后,2組患者的血小板計數(shù)均高于治療前(t=-12.528,P=0.000; t=-5.846,P=0.000),且聯(lián)合治療組患者的血小板計數(shù)高于單純西藥組[(224.23±60.28)×109個·L-1,(187.70±55.89)×109個·L-1,t=2.741,P=0.010]。④白細胞抑制程度。治療結(jié)束1周后,聯(lián)合治療組0度9例、Ⅰ度11例、Ⅱ度7例、Ⅲ度3例,單純西藥組0度4例、Ⅰ度7例、Ⅱ度8例、Ⅲ度6例、Ⅳ度5例; 聯(lián)合治療組患者的白細胞抑制程度優(yōu)于單純西藥組(Z=-2.717,P=0.007)。⑤血紅蛋白抑制程度。治療結(jié)束1周后,聯(lián)合治療組0度8例、Ⅰ度10例、Ⅱ度12例,單純西藥組0度3例、Ⅰ度10例、Ⅱ度6例、Ⅲ度6例、Ⅳ度5例; 聯(lián)合治療組患者的血紅蛋白抑制程度優(yōu)于單純西藥組(Z=-2.547,P=0.011)。⑥血小板抑制程度。治療結(jié)束1周后,聯(lián)合治療組0度11例、Ⅰ度13例、Ⅱ度4例、Ⅲ度2例,單純西藥組0度8例、Ⅰ度7例、Ⅱ度8例、Ⅲ度4例、Ⅳ度3例; 聯(lián)合治療組患者的血小板抑制程度優(yōu)于單純西藥組(Z=-2.009,P=0.045)。⑦臨床癥狀改善情況。治療結(jié)束1周后,聯(lián)合治療組顯著改善13例、部分改善14例、無效3例,單純西藥組顯著改善7例、部分改善12例、無效11例; 聯(lián)合治療組患者的臨床癥狀改善情況優(yōu)于單純西藥組(Z=-2.363,P=0.018)。⑧生活質(zhì)量。治療結(jié)束1周后,聯(lián)合治療組改善16例、穩(wěn)定10例、降低4例,單純西藥組改善9例、穩(wěn)定8例、降低13例; 聯(lián)合治療組患者的生活質(zhì)量高于單純西藥組(Z=-2.430,P=0.015)。⑨其他。治療過程中,單純西藥組6例應用促紅細胞生成素、3例輸注血小板,聯(lián)合治療組無1例采取上述措施。結(jié)論:對于惡性骨腫瘤化療后骨髓抑制患者,在采用重組人粒細胞集落刺激因子皮下注射治療的基礎上,應用健脾補腎中藥口服治療,可以增加外周血液中白細胞計數(shù)、血紅蛋白含量及血小板計數(shù),減輕骨髓抑制程度,有利于改善臨床癥狀、提高生活質(zhì)量,其療效優(yōu)于單純采用重組人粒細胞集落刺激因子皮下注射治療。
Abstract:
To observe the effects of Jianpi Bushen(健脾補腎,JPBS)traditional Chinese medicine(TCM)on peripheral hemogram of patients with myelosuppression after chemotherapy for treatment of malignant bone tumors.Methods:Sixty patients with myelosuppression after chemotherapy for malignant bone tumors were enrolled in the study and were randomly divided into 2 groups,30 cases in each group.The patients were treated with combination therapy of subcutaneous injection of recombinant human granulocyte colony-stimulating factor(rhG-CSF)and oral application of JPBS TCM(combination therapy group)and monotherapy of subcutaneous injection of rhG-CSF(monotherapy group)respectively for one course of treatment,consecutive 7 days for each course.The white blood cell(WBC)counts,hemoglobin(HGB)contents and platelet counts in peripheral blood were recorded and compared between pretreatment and posttreatment and between the 2 groups,and the inhibition degrees of WBC,HGB and platelet were evaluated.Moreover,the improvement of clinical symptoms and life quality of patients in the 2 groups were evaluated at 1 week after the end of the treatment.Results:There was no statistical difference in WBC counts between the 2 groups before the treatment(3.28±0.64 vs 3.19±0.76 ×10(9)cells/L,t=0.566,P=0.576).The WBC counts were higher at 1 week after the end of the treatment compared to pretreatment in the 2 groups(t=-6.606,P=0.000; t=-3.583,P=0.000),and were higher in combination therapy group compared to monotherapy group(8.68±1.75 vs 4.63±1.20 ×10(9)cells/L,t=10.954,P=0.000).There was no statistical difference in HGB contents between the 2 groups before the treatment(112.47±10.05 vs 108.63±9.67 g/L,t=-1.941,P=0.062).The HGB contents were higher at 1 week after the end of the treatment compared to pretreatment in the 2 groups(t=-11.750,P=0.000; t=-5.695,P=0.000),and were higher in combination therapy group compared to monotherapy group(140.83±17.36 vs 126.87±15.56 g/L,t=4.331,P=0.000)...

參考文獻/References:

[1] 張劍峰,劉寬榮.骨惡性腫瘤36例手術治療臨床分析[J].山西醫(yī)藥雜志,2015,44(1):80-82.
[2] 李建強,孫虹斐,靳宇,等.補腎益精湯聯(lián)合化療預防腫瘤患者骨髓抑制的作用及對血清G-CSF、IL-3水平的影響[J].現(xiàn)代中西醫(yī)結(jié)合雜志,2017,26(33):3708-3710.
[3] 王和鳴,黃桂成.中醫(yī)骨傷科學[M].3版.北京:中國中醫(yī)藥出版社,2012:377-378.
[4] 丁聚賢,謝興文,許偉,等.中醫(yī)藥在骨肉瘤放化療中的作用研究進展[J].中醫(yī)正骨,2018,30(5):43-46.
[5] 中華醫(yī)學會骨科學分會骨腫瘤學組.四肢骨腫瘤保肢治療指南[J].中華骨科雜志,2019,39(1):1-9.
[6] 周際昌.實用腫瘤內(nèi)科學[M].2版.北京:人民衛(wèi)生出版社,2003:537-555.
[7] 周仲瑛.中醫(yī)內(nèi)科學[M].北京:中國中醫(yī)藥出版社,2017:120-125.
[8] SCHAG C C,HEINRICH R L,GANZ P A.Karnofsky performance status revisited:reliability,and guidelines[J].J Clin Oncol,1984,2(3):187-193.
[9] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[10] CHOI Y Y,KIM J Y,YANG S O.PET/CT in benign and malignant musculoskeletal tumors and tumor-like conditions[J].Semin Musculoskelet Radiol,2014,18(2):133-148.
[11] NIU X,XU H,INWARDS C Y,et al.Primary bone tumors:epidemio-logic comparison of 9200 patients treated at Beijing Ji Shui Tan Hospital,Beijing,China,with 10165 patients at Mayo Clinic,Rochester,Minnesota[J].Arch Pathol Lab Med,2015,139(9):1149-1155.
[12] 劉宏杰,張寧,李凌云,等.甲磺酸阿帕替尼三線及以上治療晚期惡性腫瘤52例療效觀察[J].皖南醫(yī)學院學報,2020,39(3):242-245.
[13] 趙秀蘭,張星星,鄭寰宇,等.HIF相關信號轉(zhuǎn)導通路因子在宮頸癌中的研究進展[J].河北醫(yī)科大學學報,2018,39(11):1360-1364.
[14] 王國華,劉鳳玲,張振山,等.參一膠囊聯(lián)合化療治療晚期非小細胞肺癌療效觀察與血清MMP-9及TIMP-1變化[J].現(xiàn)代腫瘤醫(yī)學,2017,25(6):896-901.
[15] 元建華,李建旺,張曙波,等.吉西他濱聯(lián)合替吉奧治療鉑類方案化療失敗晚期鼻咽癌患者臨床觀察[J].中華腫瘤防治雜志,2019,26(3):170-174.
[16] HOU B,LIU R,QIN Z,et al.Oral Chinese herbal Medicine as an adjuvant treatment forchemotherapy,or radiotherapy,induced myelosuppression:a systematic review and Meta analysis of randomized controlled trials[J].Evid Based Complement Alternat Med,2017,2017(5):1-13.
[17] 顧玉蘭.粒細胞集落刺激因子在化療患者中的應用調(diào)查[J].中國癌癥防治雜志,2014,6(2):177-180.
[18] 陳丹,陳理.中醫(yī)藥防治化療后骨髓抑制的研究進展[J].江蘇中醫(yī)藥,2012,44(7):76-77.
[19] 章偉,趙林林,陳立偉,等.惡性腫瘤化療后骨髓抑制的中醫(yī)藥防治進展[J].四川中醫(yī),2014,32(6):179-182.
[20] 侯天將,尚靜,由鳳鳴,等.化療所致骨髓抑制的中醫(yī)病機要素及臨床治療分析[J].云南中醫(yī)中藥雜志,2016,37(9):31-33.
[21] 王茜,竇永起.化療后骨髓抑制的中藥防治研究進展[J].現(xiàn)代醫(yī)藥衛(wèi)生,2013,29(14):2141-2143.
[22] 陶靈佳,任建琳,季青,等.健脾補腎復方治療大腸癌靶點的網(wǎng)絡藥理學研究[J].中華中醫(yī)藥雜志,2017,32(4):1772-1774.
[23] 孫政華,邵晶,郭玫.黨參化學成分及藥理作用研究進展[J].安徽農(nóng)業(yè)科學,2015,43(33):174-176.
[24] 劉爽.黃芪藥理作用的研究進展[J].北方藥學,2015,12(12):95-96.
[25] 劉醫(yī)輝,楊世英,馬偉林,等.當歸藥理作用的研究進展[J].中國當代醫(yī)藥,2014,21(22):192-193.
[26] 祝燁.人參、黃芪、當歸對血發(fā)生的影響[J].成都中醫(yī)藥大學學報,2000,23(3):55-56.
[27] 芮鑫淼,錢佳誠,李永峰,等.健脾補腎法治療放化療后骨髓抑制研究進展[J].浙江中西醫(yī)結(jié)合雜志,2019,29(7):606-608.

相似文獻/References:

[1]朱麗英,胡春艷,孟苗,等.唑來膦酸靜脈滴注聯(lián)合華蟾素膠囊口服治療轉(zhuǎn)移性骨腫瘤[J].中醫(yī)正骨,2017,29(07):55.
[2]易春智,藍鋆,李若愚,等.冷凍消融術在骨與軟組織腫瘤治療中的應用[J].中醫(yī)正骨,2017,29(09):57.
[3]忻岳軍,陳天亮,尹彬彬.基于CT周圍神經(jīng)重建圖像判斷骨和軟組織腫瘤與鄰近神經(jīng)的關系[J].中醫(yī)正骨,2021,33(10):41.

更新日期/Last Update: 1900-01-01